The FDA has granted Mylan Pharmaceuticals approval for its fenofibrate tablets in 48 mg and 145 mg strengths to reduce levels of low-density lipoprotein cholesterol, total cholesterol, triglycerides and apolipoprotein B, and boost high-density lipoprotein cholesterol. The drug is a generic version of Abbvie's Tricor.

Full Story:
RTT News

Related Summaries